Grant: Alliance Grants
University of Waterloo
$20,000.00
Developing a cells-on-a-chip eye model to measure the retention time eye drops containing hyaluronic acid
EF 2024-25
Résumé
The aim of this project is to develop a cells-on-a-chip eye model that can measure the retention time of eye drops containing hyaluronic acid for treating dry eye disease. Dry eye disease affects more than 20% of Canadians, often leading to discomfort and vision problems. Typically, eye drops are quickly washed away after application due to natural processes such as blinking and tear drainage. It is hypothesized that by incorporating hyaluronic acid, a natural lubricant, the duration the eye drop remains in the eye can be extended, potentially enhancing its effectiveness. However, there are currently no cell-based models available to evaluate this effect. The research team will develop a cells-on-a-chip eye model using immortalized human eye cells and then utilize the model to test various eye drop formulations containing hyaluronic acid. The goal is to create a robust screening tool to identify which formulations improve retention time. This research will save the company significant time and resources in R&D, offering a clearer understanding of how new formulations might perform better before proceeding to costly clinical trials. For patients, this could lead to more effective eye drops that require fewer applications and reduce costs. For Canada, it signifies progress in eye care and enhances the company's competitiveness, potentially resulting in more jobs, increased sales, and further innovation.
Programme
Alliance Grants
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
597481-2024
Name nom
Jones, Lyndon W
Department département
Optometry, School of
Organization id
33
Institution établissement
University of Waterloo
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2024
Award amount
20000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Developing a cells-on-a-chip eye model to measure the retention time eye drops containing hyaluronic acid
Keywords
cell culture; cells-on-a-chip; human corneal epithelial cells; hyaluronic acid; in vitro eye model; microfluidic; organ-on-a-chip; retention time
Application summary
The aim of this project is to develop a cells-on-a-chip eye model that can measure the retention time of eye drops containing hyaluronic acid for treating dry eye disease. Dry eye disease affects more than 20% of Canadians, often leading to discomfort and vision problems. Typically, eye drops are quickly washed away after application due to natural processes such as blinking and tear drainage. It is hypothesized that by incorporating hyaluronic acid, a natural lubricant, the duration the eye drop remains in the eye can be extended, potentially enhancing its effectiveness. However, there are currently no cell-based models available to evaluate this effect. The research team will develop a cells-on-a-chip eye model using immortalized human eye cells and then utilize the model to test various eye drop formulations containing hyaluronic acid. The goal is to create a robust screening tool to identify which formulations improve retention time. This research will save the company significant time and resources in R&D, offering a clearer understanding of how new formulations might perform better before proceeding to costly clinical trials. For patients, this could lead to more effective eye drops that require fewer applications and reduce costs. For Canada, it signifies progress in eye care and enhances the company's competitiveness, potentially resulting in more jobs, increased sales, and further innovation.